Advantages of Singapore as a Clinical Supply Hub to be Discussed by Catalent at Accelerating Clinical Trials in Asia Conference
On Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney will present “Singapore: APAC’s Clinical Supply Gateway to the World”. She will explain the economic and regulatory advantages of locating a clinical supply hub in Singapore and will also discuss the importance of clinical supply management in optimizing drug development and launch strategy, ensuring trials are executed on time.
Ms. Delaney has more than 25 years’ experience in clinical supplies management, with over 10 years spent in the APAC region. She has held several roles in supplies management and quality assurance for several pharmaceutical companies and contract manufacturing organizations. In her current role, Ms. Delaney is responsible for Catalent’s project management teams in Singapore, China and Japan.
For further information visit www.clinical.catalent.com/events/accelerating-clinical-trials-in-asia-ibc
Notes for Editors
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com